These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 19454355

  • 1. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
    Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N, James WP, Caterson ID, Rode RA, Torp-Pedersen C, SCOUT Executive Steering Committee, SCOUT investigators.
    Metabolism; 2009 Aug; 58(8):1109-15. PubMed ID: 19454355
    [Abstract] [Full Text] [Related]

  • 2. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

  • 3. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA, Zavoral JH, Rowe E, Mendel CM, Silbutramine Study Group.
    Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
    [Abstract] [Full Text] [Related]

  • 4. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z, Placha G.
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [Abstract] [Full Text] [Related]

  • 6. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
    James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, SCOUT Investigators.
    N Engl J Med; 2010 Sep 02; 363(10):905-17. PubMed ID: 20818901
    [Abstract] [Full Text] [Related]

  • 7. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2009 Mar 02; 11(3):239-50. PubMed ID: 18671798
    [Abstract] [Full Text] [Related]

  • 8. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
    Maggioni AP, Caterson I, Coutinho W, Finer N, Gaal LV, Sharma AM, Torp-Pedersen C, Bacher P, Shepherd G, Sun R, James P, SCOUT Investigators.
    J Cardiovasc Pharmacol; 2008 Nov 02; 52(5):393-402. PubMed ID: 19033818
    [Abstract] [Full Text] [Related]

  • 9. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF, Pei D, Li JC, Tsai WC, Tsai CC, Yao CY, Chang ET, Hsieh MC, Su KY, Kuo SW.
    Int J Clin Pract; 2005 Jul 02; 59(7):746-50. PubMed ID: 15963197
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.
    Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P, SCOUT Investigators.
    Eur Heart J; 2007 Dec 02; 28(23):2915-23. PubMed ID: 17595194
    [Abstract] [Full Text] [Related]

  • 11. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
    Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2012 Jun 02; 14(6):523-30. PubMed ID: 22192338
    [Abstract] [Full Text] [Related]

  • 12. The obese older female patient: CV risk and the SCOUT study.
    Coutinho WF.
    Int J Obes (Lond); 2007 Nov 02; 31 Suppl 2():S26-30; discussion S31-2. PubMed ID: 17968434
    [Abstract] [Full Text] [Related]

  • 13. Orlistat and sibutramine beyond weight loss.
    Mannucci E, Dicembrini I, Rotella F, Rotella CM.
    Nutr Metab Cardiovasc Dis; 2008 Jun 02; 18(5):342-8. PubMed ID: 17928208
    [Abstract] [Full Text] [Related]

  • 14. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL, Apovian CM, Aronne LJ, Fernstrom MH, Frank A, Greenway FL, Heber D, Kushner RF, Cwik KM, Walch JK, Hewkin AC, Blakesley V.
    Obesity (Silver Spring); 2007 Jun 02; 15(6):1464-72. PubMed ID: 17557984
    [Abstract] [Full Text] [Related]

  • 15. High protein diets decrease total and abdominal fat and improve CVD risk profile in overweight and obese men and women with elevated triacylglycerol.
    Clifton PM, Bastiaans K, Keogh JB.
    Nutr Metab Cardiovasc Dis; 2009 Oct 02; 19(8):548-54. PubMed ID: 19179060
    [Abstract] [Full Text] [Related]

  • 16. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G, Romano C, De Caprio C, Contaldo F, Salanitri T, di Luzio Paparatti U, Pasanisi F.
    Nutr Metab Cardiovasc Dis; 2005 Feb 02; 15(1):24-30. PubMed ID: 15871847
    [Abstract] [Full Text] [Related]

  • 17. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM, Balance Study Group.
    Eur J Clin Nutr; 2005 Aug 02; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [Abstract] [Full Text] [Related]

  • 18. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May 02; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 19. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V, Sacco T, Zamboni M, Bissoli L, Zoico E, Mazzali G, Minniti A, Salanitri T, Cancelli F, Bosello O.
    Ann Nutr Metab; 2007 May 02; 51(1):75-81. PubMed ID: 17356258
    [Abstract] [Full Text] [Related]

  • 20. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
    Van Gaal LF, Caterson ID, Coutinho W, Finer N, Maggioni AP, Sharma AM, Torp-Pedersen C, Ge H, Moran SA, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2010 Jan 02; 12(1):26-34. PubMed ID: 19758358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.